Venetoclax combinations in mutant AML subtypes podcast: FLT3

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML.


Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML.


In this podcast, Daver discusses the results of a study comparing the combination of azacitidine plus venetoclax versus azacitidine plus placebo in patients with FLT3-mutated AML. He also talks about a study evaluating the combination of gilteritinib with venetoclax in patients with relapsed/refractory FLT3-mutated AML and reports the results of the first combination of decitabine + venetoclax + FLT3 inhibitor of clinician’s choice in patients with FLT3-mutated AML.


Hosted on Acast. See acast.com/privacy for more information.

More from AML Hub

  1. 03:36What were your highlights from ASH 2023?Apr 29, 2024
  2. 09:19What are the challenges associated with CAR T-cell therapy in patients with AML?Apr 25, 2024
  3. 07:27How might the MORPHO trial of gilteritinib impact clinical practice?Apr 08, 2024
  4. 11:49Risk stratification and guidelines in AML managementJan 08, 2024
  5. 06:04How are new fludarabine conditioning combinations impacting transplant outcomes?Apr 22, 2022
  6. 06:08Should pre-transplant MRD be used to guide treatment in AML?Jul 10, 2021
  7. 13:54Should pre-transplant MRD be used to guide treatment in AML?Jun 25, 2021
  8. 05:03Should pre-transplant MRD be used to guide treatment in AML?Jun 23, 2021
  9. 05:22Can HMA maintenance therapy improve eligibility for HSCT?Mar 17, 2021
  10. 16:07ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?Feb 02, 2021